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Background: Right portal vein embolization (RPVE) has been utilized with or without segment IV (RPVE
+ IV) prior to hepatectomy to induce hypertrophy and prevent liver insufficiency in patients with a
predicted future liver remnant (FLR) of 30% or cirrhosis.
Methods: Records of patients who underwent RPVE during 2006–2010 were retrospectively reviewed.
Patient demographics, operative outcomes and complications were analysed. Computed tomography-
based volumetrics were performed to determine FLR volume and degree of hypertrophy. Patients were
stratified by segment IV embolization. Short-term outcomes following RPVE and liver resection are
reported.
Results: A total of 23 patients were identified. Ten patients underwent RPVE and 13 underwent RPVE +
IV. The RPVE procedure resulted in a 38% increase in FLR volume. Liver volumes, hypertrophy rates and
outcomes were similar in both groups. Rates of operative complications in the RPVE and RPVE + IV
groups were similar at 50% and 54%, respectively, and most complications were minor. Complication
rates as a result of embolization were 30% in the RPVE group and 31% in the RPVE + IV group. One
patient underwent modified operative resection as a result of a complication of RPVE.
Conclusions: Right portal vein embolization (segment IV) is a safe and effective modality to increase
FLR volume. Post-embolization complications and short-term outcomes after resection are acceptable
and are similar in both RPVE and RPVE + IV.
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Introduction
Portal vein embolization (PVE) was introduced by Kinoshita
et al.1 and Makuuchi et al.2 to induce hypertrophy and prevent
postoperative liver insufficiency among patients undergoing
major hepatectomy. As originally described, PVE encompassed
occlusion of either a left or right second-order portal venous
branch. The procedure is now established as a technique to permit
hepatectomy in many patients with an otherwise inadequate
future liver remnant (FLR). Preoperative PVE is utilized when the
FLR is estimated to comprise <20–30% of the total liver volume in
a patient with normal hepatic parenchyma or <30–40% in a
patient with underlying liver disease.3–6
Nagino et al. introduced the concept of PVE with extension to
segment IV (PVE + IV) in patients undergoing extended right
This report is based on an abstract entitled ‘Safety and efficacy of portal vein
embolization in patients at risk for postoperative liver failure’, given as a
poster presentation during Digestive DiseaseWeek, 7–10May 2011, Chicago,
IL.
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hepatectomy.7 This technique is employed to optimize hypertro-
phy of segments II and III, but its safety and efficacy are contro-
versial. A single-institution study indicated that it improves the
hypertrophy of segments II and III compared with PVE alone
without increasing complications.8 However, others have failed to
detect any significant increase in hypertrophy of segments II and
III with the addition of segment IV embolization.9
Our institution employs a multidisciplinary team to determine
the appropriate approach to preoperative PVE and liver resection.
Currently, we use PVE in patients with an estimated FLR of30%
and normal hepatic parenchyma and in patients with an estimated
FLR of 40% and underlying liver disease. We employ segment
IV embolization when the operative plan includes an extended
right hepatectomy. In this study, we sought to analyse our short-
term outcomes after right PVE (RPVE) and subsequent operative
resection and to assess the risks and benefits associated with
segment IV embolization (RPVE + IV).
Materials and methods
Records of patients who underwent RPVE prior to major right
hepatic resection during the years 2006–2010 were retrospectively
reviewed. Patient clinical characteristics and data on procedural
and operative outcomes were obtained via electronic chart review.
The study was approved by our institutional review board.
Patients underwent liver resection carried out by one of two
surgeons during the study period. Pre-procedure three-phase
computed tomography (CT) assessment was performed at 1–71
days prior to embolization. Post-procedure CT scans were
obtained at a median of 5.1 weeks (range: 2–18 weeks) following
the procedure. In general, a 4-week interval was allowed to elapse
between PVE and follow-up CT scan. Earlier scans were obtained
in a small subset of patients to rule out disease progression. In
others, follow-up scans were delayed for logistical reasons or as a
result of complications related to PVE. Future liver remnant
volumes and predicted resection volumes were determined by
tracing the sections of liver in each transverse 5-mm slice of the
patient’s pre-procedure CT scan in the portal venous phase.10 All
values obtained were within a 5% standard deviation. The esti-
mated FLR included segment IV as defined by the lateral border of
the middle hepatic vein when a right hepatectomy was planned.
Values for standardized FLR (sFLR) were obtained according to
the following equation: sFLR = FLR volume (mL)/standardized
liver volume (mL) ¥ 100%. Values for standardized liver volume
(sLV) were calculated by the formula: sLV = -794.41 + 1267.28 ¥
body surface area (m2).11 Degree of hypertrophy was defined
as [(post-embolization sFLR - pre-embolization sFLR)/pre-
embolization sFLR] ¥ 100%.
The PVE technique was performed with ultrasound and fluo-
roscopic guidance. Ultrasound was used to obtain initial access to
the portal vein from a right lateral percutaneous approach in the
majority of patients.When access from the right required travers-
ing the tumour burden, contralateral access was obtained. After
obtaining stable access to the portal vein, a 5-Fr sheath was placed
over the wire, a flush catheter was advanced into the main portal
vein, and digital subtraction angiography (DSA) of the portal
venous anatomy was obtained. Frequently, oblique magnified
projections were required to clearly identify major divisions of
the portal vein branching pattern, as well as the portal venous
supply to segment IV. After identification, the target vessel was
selected with a wire and catheter combination to allow direct
access to the vessel. On rare occasions a high-flow microcatheter
was required to maintain stable access for both particulate and
coil embolization. Once stable access to the target vessel was
confirmed, the vessel was embolized to near stasis with
small (approximately 100-mm in diameter) complex co-polymer
embolic agents. Post-embolization DSA was performed to
confirm limited flow. Frequently, additional embolic agents
(including platinum coils sized appropriately to the vessel) were
required. Using similar techniques, the major branches to the
remainder of the targeted liver were catheterized and treated with
a combination of embolic particles and additional embolic coils.
Post-embolization DSA evaluation of the main portal vein was
performed to confirm flow to the left lobe of the liver and
minimal flow to the right lobe of the liver (with and without
segment IV, respectively). If the right main portal vein was long
enough, an Amplatzer plug (AGA Medical Corp., Plymouth, MN,
USA) was inserted to embolize it. Effort was made to maintain
enough room between the last embolic agent (coil or Amplatzer
plug) and the portal vein bifurcation to allow the direct surgical
clamp or vascular staple and ligation of the right portal vein at the
origin. The catheters and sheath were then pulled back to the
entry site of the portal venous system. The intraparenchymal tract
was embolized with gel foam slurry and/or platinum microcoils.
Completeness of embolization was assessed by a post-procedure
CT scan.
Patient clinical characteristics, liver volumes and procedural
and operative outcomes were stratified according to whether or
not segment IV embolization had been performed and then com-
pared. Postoperative complications were classified as previously
described by Dindo et al.12 Complications classified as Grade I or
II were considered minor, whereas complications of Grade III or
higher were considered major. Postoperative liver insufficiency
was defined as a peak serum bilirubin of >7.0 mg/dL.13 Normally
distributed continuous data were expressed as means and stan-
dard deviations and were compared using a one-way analysis of
variance (anova). All other continuous variables were expressed
as medians and interquartile ranges and compared using a Mann–
Whitney U-test. Categorical data were compared using Fisher’s
exact test. P-values of0.05 were considered to indicate statistical
significance for all comparisons.
Results
Clinical characteristics
Twenty-three patients underwent RPVE at our institution during
2006–2010. Patients undergoing RPVE vs. RPVE + IV were similar
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with respect to age, gender, American Society of Anesthesiologists
(ASA) score and body mass index (Table 1). Overall, 74% of these
procedures were performed in patients with colorectal cancer
metastases. The majority of patients (78%) underwent preopera-
tive chemotherapy. Of those receiving chemotherapy, 94% fol-
lowed a regimen containing oxaliplatin and completed a median
of seven cycles (range: 2–12 cycles). A total of 50% of patients
receiving chemotherapy were given bevacizumab (Avastin™).
Chemotherapy was withheld for a minimum of 4 weeks prior to
liver resection. Regimens including Avastin™ were withheld
for 6 weeks preoperatively. One patient received chemotherapy
between PVE and liver resection.Only two patients were known to
have cirrhosis preoperatively. The majority of patients (87%)
underwent definitive operative resection following PVE. Two of
the three patients who did not undergo operative resection expe-
rienced disease progression that rendered them unresectable. The
third patient was found to have macronodular cirrhosis at the
time of the planned liver resection and the decision was made to
treat the patient with radiofrequency ablation rather than liver
resection.
Volumetric assessments
Preoperative sFLR volumes were <20%, 21–30% and >30% in
30%, 40% and 30% of patients, respectively. Preoperative and
postoperative volume measurements were compared for patients
undergoing extended right hepatectomy. Results are shown in
Table 2.Median preoperative sFLR volumes were lower in patients
undergoing RPVE + IV (23.8%) compared with patients under-
going RPVE (26.5%), although the difference did not reach sta-
tistical significance. The absolute change in FLR volume did not
differ between the groups. The median degree of hypertrophy,
defined as the percentage increase in the sFLR after PVE, was
higher in those undergoing RPVE + IV (38.3%) than in those
undergoing RPVE alone (23.8%), although this difference did not
reach statistical significance.
Complications and outcomes of PVE
Complication rates after PVE were similar in the two groups
(Table 3). No patients had incomplete embolization as evaluated
by post-procedure CT scan. Five patients underwent hepatic
access via the left portal venous system because of a high right-
Table 1 Clinical characteristics of patients in the right portal vein embolization (RPVE) and RPVE + segment IV groups
Characteristic RPVE (n = 10) RPVE + IV (n = 13) P-value
Age, years, mean  SD 60.6  9.7 59.4  6.5 0.715
Male gender, n 6 8 1.000
ASA score 3, n 9 9 0.229
Body mass index, kg/m2, median (IQR) 26.0 (23.3–28.0) 28.1 (23.5–32.7) 0.321
Aetiology, n 0.118
Colorectal cancer liver metastases 6 11
Hepatocellular carcinoma 3 0
Other 1 2
Preoperative chemotherapy, n 7 11 0.618
Cirrhosis, n 1 1 1.000
Operation, n 0.068
Right hepatectomy 4 1
Extended right hepatectomy 4 11
No resection 2 1
RPVE, right portal vein embolization; RPVE + IV, right portal vein embolization plus segment IV; SD, standard deviation; IQR, interquartile range; ASA,
American Society of Anesthesiologists.
Table 2 Comparison of liver volume in patients undergoing extended right hepatectomy
RPVE (n = 6) RPVE + IV (n = 12) P-value
FLR volume pre-PVE, mL, median (IQR) 532.1 (410.7–614.2) 441.0 (256.9–513.0) 0.396
FLR volume post-PVE, mL, median (IQR) 739.4 (694.9–813.2) 579.6 (420.0–703.3) 0.052
Change in volume, mL, median (IQR) 139.9 (125.3–299.7) 140.9 (119.3–243.8) 1.000
sFLR pre-PVE, %, median (IQR) 26.5 (20.7–37.2) 23.8 (18.9–29.9) 0.777
sFLR post-PVE, %, median (IQR) 37.5 (33.3–57.2) 35.7 (24.8–42.5) 0.697
Degree of hypertrophy, %, median (IQR) 23.8 (20.7–62.3) 38.3 (26.0–87.2) 0.310
RPVE, right portal vein embolization; RPVE + IV, right portal vein embolization plus segment IV; FLR, future liver remnant; PVE, portal vein
embolization; sFLR, standardized future liver remnant; IQR, interquartile range.
16 HPB
HPB 2012, 14, 14–19 © 2011 International Hepato-Pancreato-Biliary Association
sided tumour burden. Only one of these patients experienced a
complication (subcapsular haematoma). Table 4 characterizes in
more detail the complications seen after RPVE in our series. Two
patients in the RPVE + IV group experienced post-procedure pain
and nausea and required hospital admission. One patient had a
thrombus in the superior mesenteric vein that delayed definitive
operative resection for 6 months. Two patients had subcapsular
haematomas and required intensive care unit (ICU) admission.
One of these patients needed blood product transfusion, but both
patients underwent their planned operative resection without
delay. Two patients experienced non-target embolization of a
portal vessel. One patient had non-target embolization of a
segment IVa vessel that did not impact on the planned operative
resection. Another patient had non-target embolization of a
segment II vessel that caused the patient to undergo a right hepa-
tectomy rather than the planned extended right hepatectomy. All
lesions in this patient were resected with a negative operative
margin, but a follow-up CT scan at 8 months demonstrated recur-
rence in the liver remnant.
Operative outcomes
Twenty (87%) patients underwent definitive operative resection
after PVE. Eight (40%) underwent right hepatectomy and 12
(60%) underwent extended right hepatectomy. Short-term opera-
tive outcomes are listed in Table 3. There were no differences
between the two groups in length of stay, operative blood loss or
Table 3 Short-term outcomes after right portal vein embolization (RPVE) and RPVE + segment IV
Outcome RPVE (n = 10) RPVE + IV (n = 13) P-value
Length of stay, days, median (IQR) 7 (6.25–9) 7 (5–9) 0.350
Operative blood loss, mL, median (IQR) 750 (525–1000) 800 (500–1350) 0.855
Patients requiring transfusion, n
Packed red blood cells 4 6 1.000
Fresh frozen plasma 4 5 0.673
Complications of RPVE, n 4 3 0.650
Operative complications, n 5 7 1.000
RPVE, right portal vein embolization; RPVE + IV, right portal vein embolization plus segment IV; IQR, interquartile range.
Table 4 Complications from portal vein embolization
Patient
no.
Indication Type of
embolization
PVE complication PVE outcome Surgical outcome Disease status at
last follow-up
1 Colorectal cancer
metastases
RPVE + IV Pain/nausea Hospital admission Complete resection Alive with disease at
3 months
2 Colorectal cancer
metastases
RPVE + IV Pain/nausea Hospital admission Radiofrequency
ablation as a result
of an
intraoperative
diagnosis of
cirrhosis
Alive with disease at
7 months
3 Colorectal cancer
metastases
RPVE SMV thrombus Delayed surgical
resection by 6
months
Complete resection No evidence of
disease at
42 months
4 Colorectal cancer
metastases
RPVE + IV Subcapsular
haematoma
ICU admission,
blood transfusion
Complete resection Alive with disease at
18 months
5 Colorectal cancer
metastases
RPVE Subcapsular
haematoma
ICU admission No resection
secondary to
disease
progression
Died of disease
6 Colorectal cancer
metastases
RPVE Non-target
embolization of
segment II vessel
Operative plan
changed from
extended right
hepatectomy to
right hepatectomy
Complete resection Alive with disease at
17 months
7 Colorectal cancer
metastases
RPVE Non-target
embolization of
segment IVa
vessel
No change in
operative plan
Complete resection Alive with disease at
6 months
PVE, portal vein embolization; RPVE, right portal vein embolization; RPVE + IV, right portal vein embolization plus segment IV; SMV, superior
mesenteric vein; ICU, intensive care unit.
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requirements for blood product transfusion. The overall postop-
erative complication rate was 52% (n = 12). Nine (75%) of these
patients underwent extended right hepatectomy.Most of the com-
plications were minor and included four urinary tract infections,
two wound infections, a transfusion reaction and an incisional
wound ascitic leak. Four patients (17%), all of whom underwent
extended right hepatectomy, experienced more serious complica-
tions, including one wound dehiscence, one episode of small
bowel ischaemia requiring bowel resection, one case of bacter-
aemia and one episode of posterior reversible encephalopathy
syndrome. There were no episodes of postoperative liver failure or
death.
Discussion
Our multidisciplinary team has recently adopted a protocol that
mandates the performance of RPVE in patients with normal liver
function and a predicted FLR of 30% and in patients with
impaired liver function and a predicted FLR of 40%. In patients
who are scheduled for an extended right hepatectomy, we have
favoured occlusion of the segment IV portal vein branches. Our
results indicate that RPVE is associated with a consistent hyper-
trophic effect on the FLR. Although the embolic occlusion of the
segment IV portal vessels produced a larger fractional hypertro-
phy of the planned remnant in patients undergoing extended right
hepatectomy, this difference did not reach statistical significance
compared with embolization of the right main portal vein alone.
The lack of statistical significance in this observation is likely to be
related to the relatively small numbers in each group. Although
few patients in this study had cirrhosis, 78% (n = 18) had been
treated with preoperative chemotherapy and still benefited from
significant hypertrophy. Our findings are consistent with those of
Kishi et al., who reported statistically significant improvement in
the hypertrophy of segments II and III in a larger series of patients
with functionally normal liver after the addition of segment IV
embolization to RPVE.8 Our findings differ from those reported
by Capussotti et al., who found no difference in the hypertrophy
of segments II and III in patients undergoing RPVE with segment
IV embolization vs. RPVE alone.9 In extended right hepatectomy,
we have found that the transection of a small-volume segment IV
is technically more favourable than attempting transection in a
hypertrophied segment. We believe the potential for increased
hypertrophy in segments I, II and III, coupled with the technical
advantages provided by the division of an atrophic segment IV,
represents sufficient reason to support routine preoperative
embolization of segment IV vessels in patients undergoing
planned extended right hepatectomy. The limitation of the
segment IV embolization relates to the necessity of accessing the
left portal vein and the small risk that errant embolic material will
compromise one of the vessels in the planned remnant. This
occurred in one patient in this series.
We found that although PVE-associated complications were
not associated with post-procedural mortality, they did alter
patient management. In some instances, the patient required
extended hospitalization and in one case of a misplaced coil the
patient required a substantive change in the operative plan, which
was facilitated by tumour response to chemotherapy. Unfortu-
nately, this patient suffered early disease recurrence in the liver
remnant, which might have been avoided if the planned extended
hepatectomy had been performed. Other series have reported
complication rates in PVE of 2.2–12.8%.8,14,15 A recent meta-
analysis of preoperative PVE reported overall morbidity of 2.2%
in 1088 patients and described the most common complications
as abdominal pain or discomfort, and fever.14 A recent article
discussing quality improvement for PVE categorized complica-
tions after PVE as either minor (abdominal pain, fever, nausea,
embolic material displacement without portal thrombosis) or
major (liver abscess, cholangitis, main or left portal vein throm-
bosis, subcapsular haematoma).16 The authors suggested that rates
should not exceed 20–25% for minor and 5% for major compli-
cations.16 In our series, we observed seven complications in 23
procedures, of which four (17% of patients) were minor and three
(13% of patients) were major. Although our major complication
rate is higher than previously reported rates, there were no epi-
sodes of liver insufficiency or death and none of the patients in
our series were precluded from operation as a result of a PVE
complication. Additionally, patients who underwent RPVE + IV
embolization did not require significantly more packed red blood
cells, fresh frozen plasma or platelet transfusions compared with
those undergoing RPVE alone. This is an important indicator of
adequate liver function after resection. Overall, our findings and
those of others8,14,15 underscore the conclusion that although PVE
is safe, there is potential for major andminor complications, albeit
at an acceptable level. In particular, the errant placement of
embolic material may obviate the possibility of resection with
curative intent and should be avoided.
Most importantly, our findings indicate that major hepatec-
tomy can be accomplished with a low major complication rate
and zero mortality after RPVE  IV in a select group of
chemotherapy-treated patients who would otherwise not have the
opportunity to undergo curative liver resection. Although rela-
tively few of our patients had documented cirrhosis, 78% (n = 18)
had received preoperative chemotherapy for colorectal liver
metastases (CLM). In recent years, this group has been shown to
be at risk for chemotherapy-associated steatohepatitis
(CASH).17–19 Although the predictors of CASH include obesity,
diabetes and irinotecan therapy, most patients are at risk for a
non-specific chemotherapy-associated injury to the liver.17–19 In
this group of patients, associated postoperative morbidity and
mortality following liver resection are markedly elevated.17,20
However, we had no episodes of liver failure or death in our series.
These results are consistent with those reported by Covey et al.,
who identified 0% mortality in a cohort of patients who under-
went PVE and chemotherapy for resectable CLM.21 These findings
may be explained by the robust hepatic hypertrophic response to
PVE seen in our study population. This is supported by the work
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of Ribero et al., who found an increased risk for postoperative
complications and death among patients with a limited response
to PVE defined as a post-procedure FLR of20% or hypertrophy
of 5%.22 Our results suggest that, even in a group of patients at
elevated risk for postoperative liver dysfunction, successful RPVE
facilitates major hepatectomy without postoperative liver insuffi-
ciency.
Our study has two substantial limitations. Most importantly, it
is possible that differences exist between patients undergoing
RPVE vs. RPVE + IV that were not detected because our sample
size was small. In addition, the performance of CT-based volu-
metrics is subjective and affects the estimation of the FLR. All
measurements were made by the same investigator to decrease
inter- and intra-observer variability. To control for image-based
volumetrics, we also compared the volumes of our CT-generated
estimates of the resection specimen with the measured volume of
the surgical pathology specimen. Importantly, we found no statis-
tically significant differences in these measurements.
Our experience indicates that although PVE may be performed
with an overall low complication rate, it is not without risk. In
fact, some complications may compromise a patient’s ability to
tolerate surgery or future therapy. These findings underscore the
need for the careful selection of patients for the procedure. The
selection process should be performed by a multidisciplinary
group involving hepatobiliary surgeons, interventional radiolo-
gists, hepatologists and oncologists. As is consistent with opinion
in the literature on most technically complex procedures, we
believe that RPVE (segment IV) should be performed by mul-
tidisciplinary groups capable of maintaining a high-volume clini-
cal practice, the members of which perform PVE frequently. This
will ensure that the appropriate patients derive benefit from this
procedure and that it is performed as safely as possible.
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